Results for the year ended 30 June 2026

McBride's profits and margins fell despite revenue growth and major new deals.

What the company is saying

McBride frames its 2026 results as resilient, highlighting a slight revenue increase to £934.2 million and a 0.4% rise in private label volumes. The company emphasizes its ability to manage cost pressures from the Middle East crisis, citing prompt price increases and operational discipline. Management, led by CEO Chris Smith, claims strategic momentum is intact, pointing to the completed Eurotab acquisition and a new contract with Vestacy, both described as transformational for future growth. The release stresses forward-looking benefits: Eurotab is said to be accretive to EPS from completion, and the Vestacy deal is projected to boost revenue and earnings by 15% at maturity in early 2028. The company also spotlights operational improvements, including a 29.2% safety gain and 90.0% renewable electricity usage. While the tone is confident, the narrative downplays year-on-year declines in adjusted operating profit, EBITDA, and EPS, instead focusing on shareholder returns and long-term targets.

What the data suggests

The disclosed figures show revenue up 0.8% to £934.2 million, but adjusted operating profit fell 10.7% to £59.0 million and adjusted EBITDA dropped 6.8% to £80.0 million (8.6% margin vs 9.3% prior). Adjusted basic EPS declined 2.3% to 21.6p, and net debt rose to £122.8 million (1.5x EBITDA, up from 1.2x). The company returned £18.0 million to shareholders, split across dividends, buybacks, and Employee Benefit Trust purchases. The Transformation programme delivered £15.3 million in net benefits to date, well short of the £50 million target by June 2028. The Eurotab acquisition and Vestacy contract are both recent, with no realised financial impact yet; the Vestacy deal's 15% uplift is only expected by early 2028. Operationally, safety and sustainability metrics improved, with a lost time injury rate of 0.34 (down 29.2%) and 90.0% renewable electricity usage. The company’s own explanation for profit declines centers on Q4 margin lag due to input cost inflation from the Middle East crisis. Overall, the numbers point to a business under pressure, with near-term financial deterioration offset by long-dated strategic bets.

Analysis

The announcement adopts a positive tone, highlighting revenue growth, operational improvements, and strategic initiatives. However, the underlying financials show year-on-year deterioration in key profitability metrics: adjusted operating profit, operating profit, EBITDA, and EPS all declined, while net debt and leverage increased. The narrative emphasizes future benefits from the Eurotab acquisition and the Vestacy contract, but these are forward-looking and lack immediate quantifiable impact—Eurotab is only recently acquired, and the Vestacy partnership's projected 15% revenue and earnings uplift is not expected until early 2028. The Transformation programme's realised benefits are modest (£15.3m to date vs a £50m target by June 2028), and significant capital expenditure (£31.2m) is being deployed for long-term projects (automation, SAP). The gap between narrative and evidence is most pronounced in the framing of strategic actions as imminent value drivers, despite the actual financial trajectory being negative and the benefits of new initiatives being long-dated and uncertain.

Risk flags

• ●Profitability is deteriorating: Adjusted operating profit, EBITDA, and EPS all declined year-on-year despite higher revenue, indicating margin pressure and weaker underlying performance.
• ●Leverage is rising: Net debt increased to £122.8 million (1.5x EBITDA), up from £105.2 million (1.2x), raising financial risk if profit recovery stalls or integration costs overrun.
• ●Execution risk on strategic projects: The Eurotab acquisition and Vestacy contract are both at early stages, with integration and transition work just beginning; the projected 15% uplift from Vestacy is not expected until 2028 and is contingent on successful execution.
• ●Cost environment remains volatile: Management warns of ongoing input cost uncertainty tied to geopolitical events, with further price rises likely and margin normalization not expected until Q2 2027.
• ●Transformation programme delivery risk: Only £15.3 million of the £50 million target has been realized, leaving significant execution risk to achieve the remaining benefits by June 2028.

Bottom line

McBride's 2026 results show a company facing margin compression and profit declines despite modest revenue growth and operational improvements. The strategic narrative relies heavily on future gains from the Eurotab acquisition and Vestacy contract, but these are long-dated and have yet to deliver tangible financial impact. Rising leverage and a challenging cost environment add to the risk profile, while the Transformation programme’s benefits are still mostly unrealized. For investors, the key question is whether management can deliver on ambitious targets amid persistent external pressures and integration challenges. The most important takeaway: near-term financial performance is weak, and the promised upside from new deals will not materialize until at least 2028, making execution over the next 12–24 months critical.

Announcement summary

(LON:MCB) McBride plc reported revenue of £934.2 million for the year ended 30 June 2026, up from £926.5 million in 2025, with 0.4% volume growth from private label. Adjusted operating profit was £59.0 million, compared to £66.1 million in 2025, and operating profit was £50.1 million, down from £60.2 million. Adjusted EBITDA was £80.0 million, representing 8.6% of revenue, while adjusted profit before taxation was £48.8 million. Profit before taxation was £39.9 million, and adjusted basic earnings per share were 21.6p. Basic earnings per share were 17.7p, and dividend per share increased to 3.1p. Net debt rose to £122.8 million, representing 1.5x adjusted EBITDA. The company returned £18.0 million to shareholders, including £5.2 million in dividends, £6.4 million in share buybacks, and £6.4 million in direct share purchases by the Employee Benefit Trust. The Transformation programme delivered £15.3 million in cumulative net benefits, with a target of £50 million by June 2028. Net capital expenditure was £31.2 million, focused on automation, operational upgrades, efficiency, and SAP modernisation. McBride completed the acquisition of Eurotab Group post-period, expanding its European footprint and adding solid-format cleaning technology, with the acquisition accretive to EPS from completion. A multi-year contract manufacturing agreement with Vestacy was announced in August 2026, expected to increase Group revenue and earnings by 15% at maturity in early 2028. The company recorded a lost time injury frequency rate of 0.34, a 29.2% improvement, and increased renewable electricity usage to 90.0%, reducing Scope 1 and 2 emissions by 26.0% and saving 3,867 tonnes of CO2e. The Service Excellence programme secured customer service levels of 92.0% for the year. The company exercised an extension option on its revolving credit facility in November 2025, maintaining a four-year term to November 2029. Integration activities for the Eurotab acquisition have started, and early work has begun for transition requirements and capital deployment related to the Vestacy partnership.

Disagree with this article?